Market Cap 213.72M
Revenue (ttm) 30.91M
Net Income (ttm) -74.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -240.31%
Debt to Equity Ratio 0.00
Volume 135,900
Avg Vol 143,212
Day's Range N/A - N/A
Shares Out 58.71M
Stochastic %K 19%
Beta 2.89
Analysts Strong Sell
Price Target $11.44

Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-ce...

Industry: Biotechnology
Sector: Healthcare
Phone: 617-586-3100
Address:
99 Coolidge Avenue, Suite 500, Watertown, United States
LabPsycho
LabPsycho Jun. 4 at 10:03 PM
$FHTX @theBigDollarski Exactly. And of course that is the image many think of when they see the name Foghorn. IMO, its right down there with "Gossamer ' biotech - just what I want to envision when thinking of biotech - a dusty ole spider web - LoL
1 · Reply
theBigDollarski
theBigDollarski Jun. 4 at 7:36 PM
$FHTX sad excuse for a company name......
0 · Reply
LabPsycho
LabPsycho May. 25 at 1:57 PM
$FHTX @NotBornYesterday Good post. The concern I have is so many PROTAC companies and universities working on this stuff...what is unique about FHTX assets. Yeah, the preclinical looks interesting but need something in phase 2 for solid tumors to compete I think. Your thoughts?
2 · Reply
NotBornYesterday
NotBornYesterday May. 15 at 11:10 AM
$FHTX In last 10 days, Fido and Deerfield have upped their stakes to 11.60% and 8.65%, respectively. Anybody care to guess timeframe on '909 decision? Looks like cash at end of 2Q could be ~$2.30/sh. At what share price is a '909 no-go decision already baked in? What curve balls could we get over remainder of 2026? If '909 no-go, can we still get positive surprise on LLY funding for other partnership programs? Bueller? Bueller? Anybody paying attention to this stock?
0 · Reply
Orlandotrader
Orlandotrader May. 14 at 7:57 PM
$FHTX Fart Horn. See you at 3.40 for some Snitzell.
0 · Reply
Orlandotrader
Orlandotrader May. 8 at 7:49 PM
$FHTX New position Today. A bit early but let’s Rock.
0 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 12:40 PM
$FHTX Current Stock Price: $4.68 Contracts to trade: $5.0 FHTX May 15 2026 Call Entry: $0.63 Exit: $1.02 ROI: 61% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 9:18 PM
$FHTX Share Price: $4.68 Contract Selected: Dec 18, 2026 $7.5 Calls Buy Zone: $0.96 – $1.18 Target Zone: $1.67 – $2.04 Potential Upside: 65% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
focafoca99
focafoca99 Apr. 21 at 8:47 PM
$FHTX showed new preclinical data across several programs, including complete and durable tumor regression for FHD-909 in combination with anti-PD-1 in mouse models.
0 · Reply
focafoca99
focafoca99 Apr. 9 at 7:53 PM
$FHTX will present new preclinical AACR data on FHD-909 and several degrader programs.
0 · Reply
Latest News on FHTX
Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)

2026-05-07T15:01:40.000Z - 4 weeks ago

Foghorn Therapeutics reports Q1 EPS (29c), consensus (31c)


Foghorn Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Foghorn Therapeutics Quarterly report: Q1 2026


Foghorn Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Foghorn Therapeutics Earnings release: Q1 2026


Foghorn Therapeutics Slides: Investor presentation

May 6, 2026, 7:00 AM EDT - 4 weeks ago

Foghorn Therapeutics Slides: Investor presentation


Foghorn Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Foghorn Therapeutics Proxy statement: Proxy filing


Foghorn Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Foghorn Therapeutics Proxy statement: Proxy filing


Foghorn Therapeutics Annual report: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 3 months ago

Foghorn Therapeutics Annual report: Q4 2025


Foghorn Therapeutics Earnings release: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 3 months ago

Foghorn Therapeutics Earnings release: Q4 2025


Foghorn Therapeutics Slides: Investor presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Foghorn Therapeutics Slides: Investor presentation


Foghorn Therapeutics initiated with a Buy at BTIG

2025-12-18T11:55:21.000Z - 6 months ago

Foghorn Therapeutics initiated with a Buy at BTIG


Foghorn Therapeutics initiated with a Buy at Stifel

2025-12-03T21:20:41.000Z - 6 months ago

Foghorn Therapeutics initiated with a Buy at Stifel

LLY


Foghorn Therapeutics initiated with a Buy at Guggenheim

2025-11-07T11:30:50.000Z - 7 months ago

Foghorn Therapeutics initiated with a Buy at Guggenheim


Foghorn Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 7 months ago

Foghorn Therapeutics Earnings release: Q3 2025


Foghorn Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 4:00 PM EST - 7 months ago

Foghorn Therapeutics Quarterly report: Q3 2025


Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)

2025-11-05T12:06:26.000Z - 7 months ago

Foghorn Therapeutics reports Q3 EPS (25c), consensus (30c)


Foghorn Therapeutics transferred with Buy rating at B. Riley

2025-09-17T12:40:20.000Z - 9 months ago

Foghorn Therapeutics transferred with Buy rating at B. Riley


Foghorn Therapeutics management to meet virtually with B. Riley

2025-08-05T14:45:31.000Z - 10 months ago

Foghorn Therapeutics management to meet virtually with B. Riley


Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)

2025-08-05T11:16:10.000Z - 10 months ago

Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)


Foghorn Therapeutics Earnings release: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Foghorn Therapeutics Earnings release: Q2 2025


Foghorn Therapeutics Quarterly report: Q2 2025

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Foghorn Therapeutics Quarterly report: Q2 2025


Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)

2025-05-14T11:06:24.000Z - 1 year ago

Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)


Foghorn Therapeutics sees cash runway into 2027

2025-05-14T11:06:16.000Z - 1 year ago

Foghorn Therapeutics sees cash runway into 2027


Foghorn Therapeutics Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Earnings release: Q1 2025


Foghorn Therapeutics Quarterly report: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Quarterly report: Q1 2025


Foghorn Therapeutics Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Proxy statement: Proxy Filing


Foghorn Therapeutics Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Proxy statement: Proxy Filing


Foghorn Therapeutics Transcript: AACR Annual Meeting 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Transcript: AACR Annual Meeting 2025


Foghorn Therapeutics Slides: FY 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Slides: FY 2025


Foghorn Therapeutics announces new preclinical data at AACR

2025-04-28T20:45:06.000Z - 1 year ago

Foghorn Therapeutics announces new preclinical data at AACR


Foghorn Therapeutics Annual report: Q4 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

Foghorn Therapeutics Annual report: Q4 2024


Foghorn Therapeutics Earnings release: Q4 2024

Mar 6, 2025, 4:00 PM EST - 1 year ago

Foghorn Therapeutics Earnings release: Q4 2024


Foghorn Therapeutics Quarterly report: Q3 2024

Nov 4, 2024, 9:30 AM EST - 1 year ago

Foghorn Therapeutics Quarterly report: Q3 2024


Foghorn Therapeutics Earnings release: Q3 2024

Nov 4, 2024, 9:30 AM EST - 1 year ago

Foghorn Therapeutics Earnings release: Q3 2024


Foghorn Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 1 year ago

Foghorn Therapeutics Quarterly report: Q2 2024


Foghorn Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 1 year ago

Foghorn Therapeutics Earnings release: Q2 2024


Foghorn Therapeutics Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Quarterly report: Q1 2024


Foghorn Therapeutics Earnings release: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Earnings release: Q1 2024


Foghorn Therapeutics Proxy statement: Proxy Filing

May 3, 2024, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Proxy statement: Proxy Filing


Foghorn Therapeutics Proxy statement: Proxy Filing

May 3, 2024, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Proxy statement: Proxy Filing


Foghorn Therapeutics Transcript: Status Update

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Foghorn Therapeutics Transcript: Status Update


Foghorn Therapeutics Press release: Status Update

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Foghorn Therapeutics Press release: Status Update


Foghorn Therapeutics Slides: Status Update

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Foghorn Therapeutics Slides: Status Update


Foghorn Therapeutics Earnings release: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Earnings release: Q4 2023


Foghorn Therapeutics Annual report: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Annual report: Q4 2023


Foghorn Therapeutics Quarterly report: Q3 2023

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Quarterly report: Q3 2023


Foghorn Therapeutics Earnings release: Q3 2023

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Earnings release: Q3 2023


Foghorn Therapeutics Quarterly report: Q2 2023

Aug 4, 2023, 7:00 AM EDT - 3 years ago

Foghorn Therapeutics Quarterly report: Q2 2023


LabPsycho
LabPsycho Jun. 4 at 10:03 PM
$FHTX @theBigDollarski Exactly. And of course that is the image many think of when they see the name Foghorn. IMO, its right down there with "Gossamer ' biotech - just what I want to envision when thinking of biotech - a dusty ole spider web - LoL
1 · Reply
theBigDollarski
theBigDollarski Jun. 4 at 7:36 PM
$FHTX sad excuse for a company name......
0 · Reply
LabPsycho
LabPsycho May. 25 at 1:57 PM
$FHTX @NotBornYesterday Good post. The concern I have is so many PROTAC companies and universities working on this stuff...what is unique about FHTX assets. Yeah, the preclinical looks interesting but need something in phase 2 for solid tumors to compete I think. Your thoughts?
2 · Reply
NotBornYesterday
NotBornYesterday May. 15 at 11:10 AM
$FHTX In last 10 days, Fido and Deerfield have upped their stakes to 11.60% and 8.65%, respectively. Anybody care to guess timeframe on '909 decision? Looks like cash at end of 2Q could be ~$2.30/sh. At what share price is a '909 no-go decision already baked in? What curve balls could we get over remainder of 2026? If '909 no-go, can we still get positive surprise on LLY funding for other partnership programs? Bueller? Bueller? Anybody paying attention to this stock?
0 · Reply
Orlandotrader
Orlandotrader May. 14 at 7:57 PM
$FHTX Fart Horn. See you at 3.40 for some Snitzell.
0 · Reply
Orlandotrader
Orlandotrader May. 8 at 7:49 PM
$FHTX New position Today. A bit early but let’s Rock.
0 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 12:40 PM
$FHTX Current Stock Price: $4.68 Contracts to trade: $5.0 FHTX May 15 2026 Call Entry: $0.63 Exit: $1.02 ROI: 61% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 9:18 PM
$FHTX Share Price: $4.68 Contract Selected: Dec 18, 2026 $7.5 Calls Buy Zone: $0.96 – $1.18 Target Zone: $1.67 – $2.04 Potential Upside: 65% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
focafoca99
focafoca99 Apr. 21 at 8:47 PM
$FHTX showed new preclinical data across several programs, including complete and durable tumor regression for FHD-909 in combination with anti-PD-1 in mouse models.
0 · Reply
focafoca99
focafoca99 Apr. 9 at 7:53 PM
$FHTX will present new preclinical AACR data on FHD-909 and several degrader programs.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 12 at 1:00 AM
$FHTX Q4 '25 Earnings Results & Recap Foghorn Therapeutics Inc. expects its cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures for at least twelve months, with $249.2M in deferred revenue expected through 2029 or beyond.
0 · Reply
d_risk
d_risk Mar. 12 at 12:32 AM
$FHTX - Foghorn Therapeutics Inc - 10K - Updated Risk Factors FHTX flags new risks from AI/ML use, shifting federal healthcare and FDA policies (including post-Loper regulatory uncertainty and IRA implementation), and political/administrative changes that could slow approvals, raise compliance costs, and pressure pricing, while dropping emerging-growth-company status as a distinct risk. #Biotechnology #AIMLIntegration #HealthcareRegulation #FDAApproval #PricingPressure 🟢 Added 🟠 Removed https://d-risk.ai/FHTX/10-K/2026-03-11
0 · Reply
Abron
Abron Mar. 9 at 3:51 PM
$FHTX Every day the same tning
0 · Reply
NorthStarStats
NorthStarStats Mar. 8 at 4:39 PM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $KR Score:90.00 (BREAKOUT WATCH), $SLDB Score: 95.00; MDA Conf.,Earnings,Phase 3 Trial, $GHRS Score: 95.00; Phase 3 Start Announcement, $FHTX Score: 85.00;Cash Runaway, $SBUX Score 70.00; Revenue +6% 600-650 new stores
0 · Reply
Abron
Abron Feb. 26 at 3:33 PM
$FHTX every day same thing
0 · Reply
BioTuesdays
BioTuesdays Feb. 23 at 2:51 PM
$FHTX has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today. https://biotuesdays.com/2026/02/23/foghorn-appoints-ryan-maynard-as-cfo/
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 11:36 PM
$FHTX Current Stock Price: $5.45 Contracts to trade: $5.0 FHTX Feb 20 2026 Call Entry: $2.21 Exit: $4.27 ROI: 93% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
wyoming2020
wyoming2020 Feb. 7 at 12:27 PM
$FHTX CEO big buy at Foghorn $ACIU $PDSB fam check it out
0 · Reply
kimmynjgrl
kimmynjgrl Feb. 3 at 11:19 PM
$FHTX One min video... https://youtube.com/shorts/tLWJo9AlexE?feature=share
0 · Reply
vu_jade
vu_jade Feb. 2 at 4:21 PM
$FHTX get your Foghorn LEG”horn” up
0 · Reply
vu_jade
vu_jade Jan. 28 at 8:31 PM
$FHTX ADDED
0 · Reply